

ASX/Media Release

15/09/2020

## Emerald receives TGA registration for Openly App

- **Emerald developed Openly platform has been registered with the Therapeutic Goods Administration (TGA) as a medical device**
- **The Openly technology extends Emerald's Real-World Evidence (RWE) platform and aids Emerald's clinical team to provide remote health and wellness screening for patients and workforces**
- **TGA registration highlights Emerald's commitment to meeting the highest regulatory standards**

**Emerald Clinics Limited (ASX: EMD) (Emerald or the Company)**, a Real-World Evidence company that develops remote patient monitoring technologies underpinned by a clinical services model, is pleased to announce Australia's Therapeutic Goods Administration (TGA) has registered its Openly platform as a Class 1 medical device after a detailed self-assessment process was completed by Emerald.

Emerald developed Openly as a digital health and wellness monitoring service that can be provided via smart mobile devices and backed by Emerald's clinical team. The Openly platform is also incorporating world leading smartphone technologies which, once validated, will enable the collection of contactless vital signs.

Emerald's CEO Dr Michael Winlo said the Openly technology will help Emerald's clinical team deliver best-in-class health and wellness screening which are becoming a high priority for workforces looking to get back to business post-COVID. Further information on Emerald's platform was released to the market on 22 June 2020.

"Openly helps collect relevant, real-world clinical information from individuals remotely and presents it to a clinical team who can act on that information. TGA registration demonstrates our commitment to generating the highest level of real-world evidence and allows us to provide health and wellness screening services, powered by smartphone technologies but backed by an experienced clinical team."

The TGA assesses medical devices before they can be approved for use in Australia. Devices must be included on the TGA's Australian Register of Therapeutic Goods (ARTG) before they can be lawfully sold in Australia.

Release authorised by: Dr Michael Winlo, CEO and Managing Director

### For further information:

Dr Michael Winlo  
CEO  
(08) 6559 2800  
[investors@emeraldclinics.com.au](mailto:investors@emeraldclinics.com.au)

Matt Wright  
Media/investor relations  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald's evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.